Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersHematology & Oncology Physician in Chicago, IL
NPI: 1194888610Primary Practice Location
THE UNIVERSITY OF CHICAGO MEDICAL CENTER
5700 S Maryland Ave, Chicago, IL
Primary Employer
The University of Chicago Medical Center
uchicagomedicine.org
HQ Phone
Get Thomas's Phone Numberphone_androidMobile
Get Thomas's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardIL State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 43 | 105 |
| 2 | 99205New patient office or other outpatient visit, typically 60 minutes | 17 | 17 |
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.
Authors: Jason Luke, Sunil Babu, Daniel Olson, Jose Lutzky, Andrew Poklepovic, Zeynep Eroglu, Nikhil Khushalani, Bruce Brockstein, Brian Labadie, Sigrun Hallmeyer, Vernon Sondak
Publication Date: 2021-05-04
Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma.
Authors: Thomas Gajewski, Jeffrey Sosman, Stanton Gerson, Lili Liu, Eileen Dolan, Shang Lin, Everett Vokes
Publication Date: 2005-11-10
Authors: Alegre, Maria-Luisa, Gajewski, Thomas F
Journal: Sci Am
Lead Sponsor: Immunocore Ltd
Intervention / Treatment: BIOLOGICAL: Pembrolizumab, BIOLOGICAL: Ipilimumab, DRUG: Dacarbazine, BIOLOGICAL: IMCgp100
Lead Sponsor: Genocea Biosciences, Inc.
Intervention / Treatment: DRUG: Cyclophosphamide, DRUG: Fludarabine, DRUG: IL-2, BIOLOGICAL: GEN-011
Lead Sponsor: Seagen Inc.
Collaborators: Merck Sharp & Dohme LLC
Intervention / Treatment: DRUG: Pembrolizumab, DRUG: Gemcitabine, DRUG: Nab-paclitaxel, DRUG: Intravenous (IV) SEA-CD40, DRUG: Subcutaneous (SC) SEA-CD40
